AVEO posts positive updated results from the second prespecified overall survival analysis of Fotivda for treating highly refractory metastatic renal cell carcinoma. Stock up more than 30%.

source https://finance.yahoo.com/news/aveo-surges-favorable-updated-os-154003325.html?.tsrc=rss